Clinical trial · Observational
Genomic Testing and Resulting Medical Decisions
The Use of Genomic Testing and the Resulting Medical Decisions According to Target Identification
NCT03301493CI-TRIAL-00088428completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is no evidence available about which molecular profiling methods are currently used for cancer patients in Austrian clinical practice. The construction of the registry proposed as a completely independent research endeavor, will be helpful for scientific evaluation and the establishment of highly credible data.
Conditions
Conditions (15)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Bladder | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Cancer, Breast | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cancer Cervix | — | UNRESOLVED | — |
| Cancer Colorectal | — | UNRESOLVED | — |
| Cancer Head Neck | — | UNRESOLVED | — |
| Cancer, Kidney | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Cancer Liver | — | UNRESOLVED | — |
| Cancer, Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Cancer of Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
| Cancer of Skin | Malignant Skin Neoplasm | ALIAS |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genomic testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Types of:molecular profiling methods
- timeFrame
- 3 years
- description
- To describe types of:molecular profiling methods used in the Austrian registry centres
- measure
- Types of cancer, for which comprehensive molecular profiling is used
- timeFrame
- 3 years
- description
- To describe types of cancer, for which comprehensive molecular profiling is used
- measure
- Timing of molecular profiling
- timeFrame
- 3 years
- description
- To describe the timing of molecular profiling in relation to stage of the disease (e.g. at diagnosis, after surgery, radiation therapy, after first/second/third/late line)
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: This registry will include cancer patients for which broad genomic profiling is indicated as assessed by the medical need and as deemed appropriate by the physician, for example * cancer with high mutational load and suspicion of regular or frequent formation of neoantigens * skin, lung, stomach, esophagus, colorectum, bladder, uterus, cervix, liver, head and neck, kidney, breast * lymphoma B-cell * any other neoplastic disease where molecular targeting is performed but treatment fails * cancer of unknown primary origin (CUP) * planned or already carried out comprehensive genomic testing as of Jan 1, 2016 note: this registry will not initially register patients who are tested for only 1-5 mutations by conventional means, but patients undergoing genomic profiling based on NGS) * a patient´s signed informed consent * Patients ≥ 18 years of age Exclusion Criteria: * Due to the non-interventional design of the registry there are no specific exclusion criteria.
References
Publications (1)
- DERIVEDHeregger R, Huemer F, Hutarew G, Hecht S, Cheveresan L, Kotzot D, Schamschula E, Rinnerthaler G, Melchardt T, Weiss L, Greil R. Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. ESMO Open. 2021 Aug;6(4):100233. doi: 10.1016/j.esmoop.2021.100233. Epub 2021 Aug 7. PMID 34371380